Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome

What Was Tested

This randomized controlled trial paper looks at NAD+ in the context of chronic fatigue syndrome and me.

CFS is a potentially disabling condition of unknown etiology.

Although its clinical presentation is associated to a myriad of symptoms, fatigue is a universal and essential finding for its diagnosis.

Who Took Part

According to the abstract, 31 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A total of 31 patients fulfilling the Centers for Disease Control criteria for CFS, were randomly assigned to either NADH or nutritional supplements and psychological therapy for 24 months.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the NAD+ group and the comparison group should start out alike.

The timeline in the abstract includes 24 months.

A thorough medical history, physical examination and completion of a questionnaire on the severity of fatigue and other symptoms were performed each trimester of therapy.

In addition, all of them underwent evaluation in terms of immunological parameters and viral antibody titers.

Statistical analysis was applied to the demographic data, as well as to symptoms scores at baseline and at each trimester of therapy.

What Was Measured

PubMed files the paper under topics including Dietary Supplements, Fatigue Syndrome, Chronic, NAD, Psychotherapy and Surveys and Questionnaires.

What This Means in Plain Language

The paper is a randomized study of NAD+ in 31 patients in people with chronic fatigue syndrome and me over 24 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2004 (Puerto Rico health sciences journal), a journal based in Puerto Rico.

More context: the NAD+ compound page, Chronic fatigue syndrome and ME research.